Department
Gastroenterology
IBD, Ulcerative Colitis, Crohn's Disease
HBOT Applications
Ulcerative Colitis
Systematic reviews indicate HBOT may achieve response rates exceeding 80% in acute severe ulcerative colitis refractory to conventional therapy, reversing chronic intestinal hypoxia.
Protocol
Pressure
2.0 – 2.4 ATA
Duration
90 min
Sessions
20 – 40
Frequency
Once daily, 5×/week
Evidence basis: Level A Meta-Analysis
Crohn's Disease
Meta-analyses demonstrate significant mucosal healing and clinical remission in Crohn's disease patients treated with HBOT, particularly for perianal fistulizing disease.
Protocol
Pressure
2.0 – 2.4 ATA
Duration
90 min
Sessions
20 – 40
Frequency
Once daily, 5×/week
Evidence basis: Level A Meta-Analysis
Inflammatory Bowel Disease (IBD)
HBOT reverses chronic intestinal hypoxia, reduces mucosal inflammation, and promotes epithelial healing. Considered a promising adjunctive therapy for IBD management.
Protocol
Pressure
2.0 – 2.4 ATA
Duration
90 min
Sessions
20 – 40
Frequency
Once daily, 5×/week
Evidence basis: Level A Meta-Analysis